[ 18 F]Fluorodeoxyglucose position emission tomography for differential diagnosis of depressive cognitive impairment: incremental value compared with clinical diagnosis
- 8 May 2025
- journal article
- Published by Royal College of Psychiatrists in The British Journal of Psychiatry
- Vol. 228 (4) , 332-339
Abstract
Background: Assessment of regional glucose metabolism by [ 18 F]fluorodeoxyglucose position emission tomography ([ 18 F]FDG PET) serves as a biomarker for differential diagnosis of dementia. Conversely, depressive cognitive impairment shows no abnormalities on cerebral [ 18 F]FDG PET. Aims: This study validates the diagnostic value of [ 18 F]FDG PET in addition to clinical diagnosis in a real-life gerontopsychiatric clinical population. Method: Ninety-eight consecutive patients with depression and cognitive impairment were included. Baseline clinical diagnoses were independently established before and after disclosure of [ 18 F]FDG PET, and dichotomised into neurodegenerative or non-neurodegenerative diseases (level 1). Subsequently, neurodegenerative cases were allocated to diagnostic subgroups (Alzheimer’s disease, Lewy body diseases, frontotemporal lobar degeneration, neurodegenerative other; level 2). An interdisciplinary, biomarker-supported consensus diagnosis after a median follow-up of 6.6 month after [ 18 F]FDG PET served as reference. Changes of clinical diagnoses and diagnostic accuracy were assessed. Results: After disclosure of [ 18 F]FDG PET, level-1 clinical diagnoses changed in 23% (95% CI 16–33%) of cases, improving the diagnostic accuracy from 72% (95% CI 62–81%) to 92% (95% CI 84–96%) ( P < 0.001). [ 18 F]FDG PET was of particular value for exclusion of neurodegenerative disease. Concerning level-2 decisions, the clinical diagnoses changed in 30% (95% CI 21–40%) of cases, increasing its accuracy from 64% (95% CI 54–74%) to 85% (95% CI 76–91%) ( P < 0.001). A major fraction of incorrect level-2 diagnoses comprised Alzheimer’s disease misdiagnosed as Lewy body diseases. Conclusions: [ 18 F]FDG PET provides a significant incremental diagnostic value beyond the clinical diagnosis in depressive cognitive impairment. Thus, [ 18 F]FDG PET should be considered in the diagnostic work-up of patients with mental disorders and cognitive impairment.Keywords
This publication has 38 references indexed in Scilit:
- The diagnostic performance of functional dopaminergic scintigraphic imaging in the diagnosis of dementia with Lewy bodies: an updated systematic reviewEuropean Journal of Nuclear Medicine and Molecular Imaging, 2023
- Neuropathology of depression in non-demented older adults: A large postmortem study of 741 individualsNeurobiology of Aging, 2022
- Brain Regional Glucose Metabolism, Neuropsychiatric Symptoms, and the Risk of Incident Mild Cognitive Impairment: The Mayo Clinic Study of AgingThe American Journal of Geriatric Psychiatry, 2021
- Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [18F]FDG PETEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- Clinical utility of FDG-PET for the differential diagnosis among the main forms of dementiaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2018
- APOEgene and neuropsychiatric disorders and endophenotypes: A comprehensive reviewAmerican Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2016
- Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairmentAlzheimer's & Dementia, 2015
- Mapping the depressed brain: A meta-analysis of structural and functional alterations in major depressive disorderJournal of Affective Disorders, 2012
- Validation of Consensus Panel Diagnosis in DementiaArchives of Neurology, 2010
- The functional neuroanatomy of geriatric depressionInternational Journal of Geriatric Psychiatry, 2009